Lisata Therapeutics
View On Demand

On A Fast Track To Treating Pancreatic Cancer

About the Event

With a focus on rapidly advancing a novel solid tumor targeting and penetration technology to improve the efficacy of anticancer drugs, Lisata has:

  • A seasoned management with a track record of more than two dozen successful product launches, including major oncology products
  • A platform technology with multiple clinical stage programs underway
  • A wealth of significant milestones over the next 24 months
  • Fast Track and Orphan Drug Designations granted by the U.S. FDA in pancreatic ductal adenocarcinoma (PDAC)

Watch this webinar with Lisata’s President and CEO, David J. Mazzo, PhD, to hear how their platform technology uniquely addresses the two challenges that plague the successful treatment of solid tumors, specifically and selectively targeting the tumor and, more importantly, facilitating the penetration of drugs through the harsh protective coating these tumors produce.

View On Demand


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.